519 related articles for article (PubMed ID: 7483773)
1. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
Johnson H; Hillary IB; McQuoid G; Gilmer BA
Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
[TBL] [Abstract][Full Text] [Related]
2. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Wang Z; Yan R; He H; Li Q; Chen G; Yang S; Chen E
PLoS One; 2014; 9(2):e89361. PubMed ID: 24586717
[TBL] [Abstract][Full Text] [Related]
3. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
4. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.
Boulianne N; De Serres G; Ratnam S; Ward BJ; Joly JR; Duval B
Vaccine; 1995 Nov; 13(16):1611-6. PubMed ID: 8578850
[TBL] [Abstract][Full Text] [Related]
5. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
6. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
[TBL] [Abstract][Full Text] [Related]
8. [35-year measles, mumps, rubella vaccination assessment in France].
Reinert P; Soubeyrand B; Gauchoux R
Arch Pediatr; 2003 Nov; 10(11):948-54. PubMed ID: 14613687
[TBL] [Abstract][Full Text] [Related]
9. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
Heath TC; Burgess MA; O'Brien ED
Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
[No Abstract] [Full Text] [Related]
10. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
11. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
Davidkin I; Valle M; Julkunen I
Vaccine; 1995 Nov; 13(16):1617-22. PubMed ID: 8578851
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
[TBL] [Abstract][Full Text] [Related]
13. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
Amela C; Pachón I; de Ory F
Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
Böttiger M; Christenson B; Strandell A; Romanus V
Dev Biol Stand; 1986; 65():37-43. PubMed ID: 3556776
[TBL] [Abstract][Full Text] [Related]
16. [Measles, mumps and rubella vaccination status of school beginners in Munich].
Markuzzi A; Schlipköter U; Weitkunat R; Meyer G
Soz Praventivmed; 1997; 42(3):133-43. PubMed ID: 9334085
[TBL] [Abstract][Full Text] [Related]
17. Measles mumps rubella (MMR) vaccine in Japan.
Kuno-Sakai H; Kimura M
Acta Paediatr Jpn; 1988 Apr; 30(2):167-74. PubMed ID: 3149851
[No Abstract] [Full Text] [Related]
18. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination.
Mahamud A; Masunu-Faleafaga Y; Walls L; Williams N; Garcia P; Teshale E; Williams R; Dulski T; Bellini WJ; Kutty PK
Vaccine; 2013 Aug; 31(36):3683-7. PubMed ID: 23770334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
